PDF(Pubmed)
Abstract：
UNASSIGNED: GATA3 immunohistochemistry has been described as a highly sensitive marker in determining carcinomas of breast and urothelial origin. In the gynecologic system, it can be used as a marker to diagnose mesonephric or mesonephric-like carcinomas and trophoblastic tumors. The present study was performed to determine the diagnostic value of GATA3 in gynecological adenocarcinomas.
UNASSIGNED: A total of 187 samples from different types of endometrial, endocervical, and ovarian carcinomas were analyzed for intensity and percentage of GATA3 expression in tumor cells. The relationship between GATA3 expression and clinicopathological parameters was investigated.
UNASSIGNED: A total of 187 patients including 101 ovarian, 77 endometrial, and 9 endocervical adenocarcinomas were investigated. Weak and focal expression of this marker was observed in 5. 1% (4/77) endometrial, 12.9% (13/101) ovarian, and 11.1% (1/9) endocervical adenocarcinomas. The mean H score in all subtypes was less than 10.6 (2-35). There was no statistically significant correlation between GATA3 expression in tumor cells with clinical stage, and tumor recurrence or metastasis.
UNASSIGNED: GATA3 is infrequently, weak, or focally expressed in most of the common gynecological adenocarcinomas.
UNASSIGNED: A total of 187 samples from different types of endometrial, endocervical, and ovarian carcinomas were analyzed for intensity and percentage of GATA3 expression in tumor cells. The relationship between GATA3 expression and clinicopathological parameters was investigated.
UNASSIGNED: A total of 187 patients including 101 ovarian, 77 endometrial, and 9 endocervical adenocarcinomas were investigated. Weak and focal expression of this marker was observed in 5. 1% (4/77) endometrial, 12.9% (13/101) ovarian, and 11.1% (1/9) endocervical adenocarcinomas. The mean H score in all subtypes was less than 10.6 (2-35). There was no statistically significant correlation between GATA3 expression in tumor cells with clinical stage, and tumor recurrence or metastasis.
UNASSIGNED: GATA3 is infrequently, weak, or focally expressed in most of the common gynecological adenocarcinomas.
摘要：
■GATA3免疫组织化学已被描述为确定乳腺癌和尿路上皮起源的高度敏感的标志物。在妇科系统中，它可以作为诊断中肾或中肾样癌和滋养细胞肿瘤的标志物。本研究旨在确定GATA3在妇科腺癌中的诊断价值。
■总共187个来自不同类型子宫内膜的样本，宫颈内膜，分析卵巢癌中GATA3表达的强度和百分比。研究GATA3表达与临床病理参数之间的关系。
■总共187名患者，包括101名卵巢患者，77子宫内膜，并对9例宫颈腺癌进行了研究。在5。1%(4/77)子宫内膜，12.9%(13/101)卵巢,11.1％（1/9）宫颈腺癌。所有亚型的平均H评分均小于10.6（2-35）。GATA3在肿瘤细胞中的表达与临床分期无统计学意义,肿瘤复发或转移。
■GATA3不常见，弱,或在大多数常见的妇科腺癌中局灶性表达。
■总共187个来自不同类型子宫内膜的样本，宫颈内膜，分析卵巢癌中GATA3表达的强度和百分比。研究GATA3表达与临床病理参数之间的关系。
■总共187名患者，包括101名卵巢患者，77子宫内膜，并对9例宫颈腺癌进行了研究。在5。1%(4/77)子宫内膜，12.9%(13/101)卵巢,11.1％（1/9）宫颈腺癌。所有亚型的平均H评分均小于10.6（2-35）。GATA3在肿瘤细胞中的表达与临床分期无统计学意义,肿瘤复发或转移。
■GATA3不常见，弱,或在大多数常见的妇科腺癌中局灶性表达。
